Z. Nabi , D. Megias , P. Diez , A. Caraman , R. Mir , D. Wheatley , M. Maclennan , J. Bliss , J. Haviland , M.A. Sydenham , E. Spezi , Y. Tsang , A.M. Brunt
{"title":"乳腺癌放疗中区域淋巴结划分的可变性及其剂量学影响","authors":"Z. Nabi , D. Megias , P. Diez , A. Caraman , R. Mir , D. Wheatley , M. Maclennan , J. Bliss , J. Haviland , M.A. Sydenham , E. Spezi , Y. Tsang , A.M. Brunt","doi":"10.1016/j.clon.2025.103836","DOIUrl":null,"url":null,"abstract":"<div><h3><em>Aims</em></h3><div>To quantify the interobserver variability of regional lymph node delineation for breast cancer radiotherapy (RT) and establish whether a relationship exists between contouring variations and dosimetry using the FAST-Forward (FF) pre-trial RT quality assurance (QA) benchmark cases.</div></div><div><h3><em>Materials and methods</em></h3><div>As part of the pre-trial RT QA, local site principal investigators (PIs) were asked to complete a single outlining QA benchmark case involving the delineation of axillary lymph node clinical target volumes (LNCTVs) levels 1–4. These contours were evaluated for concordance against an expert defined consensus gold standard (GS) volume using various conformity indices (CIs): discordance index (DI), geographical miss index (GMI), Jaccard index (JCI), mean distance to conformity (MDC) for both over- and under- contouring. Descriptive statistics including interquartile range (IQR) was used to evaluate interobserver variation. Wilcoxon signed-rank tests were used to establish if there were any statistically significant differences in the dosimetric parameters between plans conforming to GS volume and the volumes from the individual PI.</div></div><div><h3><em>Results</em></h3><div>Pre-trial outlining QA benchmark cases from 29/33 PIs were assessed. The median submitted LNCTV volume was 131.4 cc (IQR: 112.4 – 145.3) compared with the GS volume of 105.46 cc. For conformity indices, the median DI was 0.37 (IQR: 0.31 – 0.40), the median GMI was 0.21 (IQR: 0.13 – 0.28), the median JCI was 0.53 (IQR: 0.49 – 0.56), MDC<sub>under</sub> was -0.43 (IQR: -0.64 - -0.32) and MDC<sub>over</sub> was 0.46 (IQR: 0.43 – 0.53). A dosimetric analysis showed all plans met the mandatory planning dose constraints but not the optimal objectives for target volumes as required in the trial protocol. Statistically significant differences were found in 7/13 organs at risk dosimetric parameters between plans conformed to individual PI volumes and the GS volume.</div></div><div><h3><em>Conclusion</em></h3><div>Analysis of the FF pre-trial QA outlining benchmark case highlights the interobserver variation that exists in axillary nodal CTV (levels 1–4) delineation. Conformity indices demonstrated moderate agreement with a median Jaccard conformity index of 0.53, with both under- and over-contouring observed. All QA submissions achieved the mandatory planning dose constraints but not all optimal dose objectives of the FF trial despite the interobserver variation in target volume contouring.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"42 ","pages":"Article 103836"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy\",\"authors\":\"Z. Nabi , D. Megias , P. Diez , A. Caraman , R. Mir , D. Wheatley , M. Maclennan , J. Bliss , J. Haviland , M.A. Sydenham , E. Spezi , Y. Tsang , A.M. Brunt\",\"doi\":\"10.1016/j.clon.2025.103836\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3><em>Aims</em></h3><div>To quantify the interobserver variability of regional lymph node delineation for breast cancer radiotherapy (RT) and establish whether a relationship exists between contouring variations and dosimetry using the FAST-Forward (FF) pre-trial RT quality assurance (QA) benchmark cases.</div></div><div><h3><em>Materials and methods</em></h3><div>As part of the pre-trial RT QA, local site principal investigators (PIs) were asked to complete a single outlining QA benchmark case involving the delineation of axillary lymph node clinical target volumes (LNCTVs) levels 1–4. These contours were evaluated for concordance against an expert defined consensus gold standard (GS) volume using various conformity indices (CIs): discordance index (DI), geographical miss index (GMI), Jaccard index (JCI), mean distance to conformity (MDC) for both over- and under- contouring. Descriptive statistics including interquartile range (IQR) was used to evaluate interobserver variation. Wilcoxon signed-rank tests were used to establish if there were any statistically significant differences in the dosimetric parameters between plans conforming to GS volume and the volumes from the individual PI.</div></div><div><h3><em>Results</em></h3><div>Pre-trial outlining QA benchmark cases from 29/33 PIs were assessed. The median submitted LNCTV volume was 131.4 cc (IQR: 112.4 – 145.3) compared with the GS volume of 105.46 cc. For conformity indices, the median DI was 0.37 (IQR: 0.31 – 0.40), the median GMI was 0.21 (IQR: 0.13 – 0.28), the median JCI was 0.53 (IQR: 0.49 – 0.56), MDC<sub>under</sub> was -0.43 (IQR: -0.64 - -0.32) and MDC<sub>over</sub> was 0.46 (IQR: 0.43 – 0.53). A dosimetric analysis showed all plans met the mandatory planning dose constraints but not the optimal objectives for target volumes as required in the trial protocol. Statistically significant differences were found in 7/13 organs at risk dosimetric parameters between plans conformed to individual PI volumes and the GS volume.</div></div><div><h3><em>Conclusion</em></h3><div>Analysis of the FF pre-trial QA outlining benchmark case highlights the interobserver variation that exists in axillary nodal CTV (levels 1–4) delineation. Conformity indices demonstrated moderate agreement with a median Jaccard conformity index of 0.53, with both under- and over-contouring observed. All QA submissions achieved the mandatory planning dose constraints but not all optimal dose objectives of the FF trial despite the interobserver variation in target volume contouring.</div></div>\",\"PeriodicalId\":10403,\"journal\":{\"name\":\"Clinical oncology\",\"volume\":\"42 \",\"pages\":\"Article 103836\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0936655525000913\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0936655525000913","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy
Aims
To quantify the interobserver variability of regional lymph node delineation for breast cancer radiotherapy (RT) and establish whether a relationship exists between contouring variations and dosimetry using the FAST-Forward (FF) pre-trial RT quality assurance (QA) benchmark cases.
Materials and methods
As part of the pre-trial RT QA, local site principal investigators (PIs) were asked to complete a single outlining QA benchmark case involving the delineation of axillary lymph node clinical target volumes (LNCTVs) levels 1–4. These contours were evaluated for concordance against an expert defined consensus gold standard (GS) volume using various conformity indices (CIs): discordance index (DI), geographical miss index (GMI), Jaccard index (JCI), mean distance to conformity (MDC) for both over- and under- contouring. Descriptive statistics including interquartile range (IQR) was used to evaluate interobserver variation. Wilcoxon signed-rank tests were used to establish if there were any statistically significant differences in the dosimetric parameters between plans conforming to GS volume and the volumes from the individual PI.
Results
Pre-trial outlining QA benchmark cases from 29/33 PIs were assessed. The median submitted LNCTV volume was 131.4 cc (IQR: 112.4 – 145.3) compared with the GS volume of 105.46 cc. For conformity indices, the median DI was 0.37 (IQR: 0.31 – 0.40), the median GMI was 0.21 (IQR: 0.13 – 0.28), the median JCI was 0.53 (IQR: 0.49 – 0.56), MDCunder was -0.43 (IQR: -0.64 - -0.32) and MDCover was 0.46 (IQR: 0.43 – 0.53). A dosimetric analysis showed all plans met the mandatory planning dose constraints but not the optimal objectives for target volumes as required in the trial protocol. Statistically significant differences were found in 7/13 organs at risk dosimetric parameters between plans conformed to individual PI volumes and the GS volume.
Conclusion
Analysis of the FF pre-trial QA outlining benchmark case highlights the interobserver variation that exists in axillary nodal CTV (levels 1–4) delineation. Conformity indices demonstrated moderate agreement with a median Jaccard conformity index of 0.53, with both under- and over-contouring observed. All QA submissions achieved the mandatory planning dose constraints but not all optimal dose objectives of the FF trial despite the interobserver variation in target volume contouring.
期刊介绍:
Clinical Oncology is an International cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. Papers, editorials and reviews are published on all types of malignant disease embracing, pathology, diagnosis and treatment, including radiotherapy, chemotherapy, surgery, combined modality treatment and palliative care. Research and review papers covering epidemiology, radiobiology, radiation physics, tumour biology, and immunology are also published, together with letters to the editor, case reports and book reviews.